“Market Cap $28.98 B As of May 2014
At a Glance
- Industry: Pharmaceuticals
- Founded: 1986
- Country: Ireland
- CEO: Flemming Ornskov
- Website: www.shire.com
- Employees: 5,338
- Sales: $5 B
- Headquarters: Dublin
#1041 Global 2000
- #1693 in Sales
- #891 in Profit
- #371 in Market value
Shire Plc is a biopharmaceutical company that focuses on meeting the needs of physicians. It focuses its business on attention deficit hyperactivity disorder, human genetic therapies and gastrointestinal diseases, as well as opportunities in other therapeutic areas. It operates under three segments which include Specialty Pharma, Human Genetic Therapies and Regenerative Medicine. The Specialty Pharmaceuticals segment focuses on small-molecule medications, including Vyvanse for the treatment of attention deficit hyperactivity disorder in children aged 6 to 17, FOSRENOL for the treatment of chronic kidney disease in pre-dialysis patients, XAGRID for the treatment of essential thrombocythaemia, JUVISTA for the improvement of scar appearance, LIALDA/MEZAVANT for the treatment of diverticulitis and RESOLOR for the treatment of chronic constipation in males. The Human Genetic Therapies segment offers products, including FIRAZYR for the treatment of acute hereditary angioedema, REPLAGAL for fabry disease and HGT-2310 for the treatment of Hunter syndrome with central nervous system symptoms, idursulfase-intrathecal delivery. The Regenerative Medicine segment focuses on Dermagraft, a bioengineered skin substitute that assists in restoring damaged tissue and supports the body’s natural healing process. The company was founded in 1986 and is headquartered in Dublin, Ireland.“
“Shire Corporate History
Our success so far stems from our single-minded determination to focus on our patients and our willingness to adapt to changing environments.
In 1986 in the UK, Shire founders forged a singular path – setting into motion a company whose people dare to believe that collaborative work and uncompromising focus can transform ideas into products that measurably change the lives of patients.
Within our first two years of operation, we had launched a range of supplemental calcium products for patients seeking to treat or prevent osteoporosis. Soon thereafter innovative drug development programs were under way on behalf of patients facing such challenging conditions as Alzheimer’s disease and end-stage renal failure. By 1992 Shire had embarked on the first of what would be a series of strategic acquisitions —bold ventures that fortified the product lines and underscored the wisdom of a business model focused exclusively on products sold to specialty physicians. The Shire pipeline continues to be sustained by creative acquisitions and innovative licensing deals. Smart commercialization strategies have ensured that the right patients and physicians have the information they need to make appropriate choices about treatment options.
Today we are a company with a portfolio of top-selling products and a promising pipeline. So naturally, we consistently attract some of the brightest talent in the industry – people who think bigger. People who see opportunity where others see obstacles. People who go to work with the expectation of making something significant happen.
With major operations in the US, UK and Switzerland, and a network of offices and distribution channels throughout Europe, South America, Canada, and the Pacific Rim, Shire employs over 5,000 people in 29 countries who continue to carry forward many of the original attributes of its founders—opportunistic thinking, transparent behavior, a deep commitment to doing what is right, and a prevailing concern for the patients and caregivers served by its well-differentiated product lines.”
*Information from Forbes.com and Shire.com
**Video published on YouTube by “BSCCevents“